Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report published on Monday morning. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright reaffirmed a buy rating and issued a $19.00 target price on shares of Oncternal Therapeutics in a research note on Tuesday, July 16th.

Oncternal Therapeutics Trading Down 2.8 %

Shares of Oncternal Therapeutics stock opened at $6.86 on Monday. Oncternal Therapeutics has a 12 month low of $5.57 and a 12 month high of $13.14. The company has a market capitalization of $20.31 million, a PE ratio of -0.56 and a beta of 1.36. The stock’s fifty day simple moving average is $8.02 and its 200 day simple moving average is $8.49.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its earnings results on Thursday, May 9th. The company reported ($2.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.88) by $0.05. Oncternal Therapeutics had a negative return on equity of 107.67% and a negative net margin of 3,160.73%. The business had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.18 million. During the same period in the prior year, the business earned ($4.00) EPS. Analysts predict that Oncternal Therapeutics will post -11.63 EPS for the current fiscal year.

Institutional Trading of Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned approximately 0.84% of Oncternal Therapeutics at the end of the most recent reporting period. 16.05% of the stock is currently owned by hedge funds and other institutional investors.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.